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Despite decades of research and clinical practice, the pathogenesis of
hypertension remains incompletely understood, and blood pressure is
often suboptimally controlled. “Omics” technologies allow the
description of a large number of molecular features and have the
potential to identify new factors that contribute to blood pressure
regulation and how they interact. In this review, we focus on the po-
tential of genomics, transcriptomics, proteomics, and metabolomics
and explore their roles in unraveling the pathophysiology and diagnosis
of hypertension, the prediction of organ damage and treatment
response, and monitoring treatment effect. Substantial progress has
been made in the area of genomics, in which genome-wide association
studies have identified > 50 blood pressureerelated, single-nucleotide
polymorphisms, and sequencing studies (especially in secondary forms
of hypertension) have discovered novel regulatory pathways. In
contrast, other omics technologies, despite their ability to provide
detailed insights into the physiological state of an organism, have only
more recently demonstrated their impact on hypertension research
and clinical practice. The majority of current proteomic studies focus
on organ damage resulting from hypertension and may have the po-
tential to help us understand the link between blood pressure and
organ failure but also serve as biomarkers for early detection ofReceived for publication October 12, 2016. Accepted November 30, 2016.
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La pathogenèse de l’hypertension demeure toujours partiellement
incomprise en depit de decennies de recherche et de pratique clinique,
ce qui fait en sorte qu’on peine encore souvent à maîtriser de manière
optimale la pression arterielle (PA) des patients. Les technologies
« omiques » permettent de decrire un nombre important de car-
acteristiques moleculaires tout en fournissant la possibilite de cibler
de nouveaux facteurs ayant une incidence sur la regulation de la PA et
sur leurs interactions. Dans cet article, nous mettons l’accent sur le
potentiel de la genomique, de la transcriptomique, de la proteomique
et de la metabolomique ainsi que leur rôle dans l’elucidation de la
physiopathologie et le diagnostic de l’hypertension, la prediction des
dommages organiques et de la reponse au traitement ainsi que la
surveillance des effets du traitement de l’hypertension. D’importants
progrès ont ete realises grâce à la genomique puisque les etudes
d’association pangenomiques ont permis jusqu’ici d’identifier plus
d’une cinquantaine de polymorphismes de nucleotides individuels
ayant une incidence sur la pression arterielle et que les etudes de
sequençage (particulièrement en ce qui a trait aux formes secondaires
d’hypertension) ont permis de mettre au jour de nouvelles voies de
regulation. Les autres technologies « omiques », en depit de leur
capacite à fournir un portrait detaille de l’etat physiologique d’unHypertension is a condition that is difficult to define. Over
the years, guideline committees and scientific societies have
suggested definitions that are based on blood pressure values,
long-term risk, and treatment effects. A recent Lancet Com-
mission report pragmatically categorizes individuals as hy-
pertensive “when they persistently cross the blood pressure
threshold above which there is robust scientific evidence that
antihypertensive treatment will improve their prognosis.” This
definition is based on the finding that blood pressure levels, at
least within a wide range, are continuously related to cardio-
vascular risk and that there is no biologically plausible blood
pressure threshold at which normal physiology becomes apathologic process.1 The challenges in the definition of hy-
pertension are important in the context of this review and in
the wider context of precision medicine in this series of articles
in the Canadian Journal of Cardiology, in which precise mo-
lecular biology methods are applied to a condition that is
inconsistently defined.
In this article, we explore how “omics” technologies can
further our understanding of the pathophysiology of hyper-
tension and influence patient management. We focus on
specific omics technologies and on human studies but
appreciate that a wealth of data has been generated in rodent
and other experimental models.The Role of Omics Technologies in
Cardiovascular Diseases
Cardiovascular diseases generally result from interaction
between genetic factors and environmental influences. The
relative contribution of these components to disease pheno-
type varies. For example, blood pressure in patients withdian Cardiovascular Society. This is an open access article under the CC BY
cerebrovascular or coronary disease. Examples include signatures for
early detection of left ventricular dysfunction or albuminuria. Metab-
olomic studies have the potential to integrate environmental and
intrinsic factors and are particularly suited to monitor the response to
treatment. We discuss examples of omics studies in hypertension and
explore the challenges related to these novel technologies.
organisme, n’ont que tout recemment laisser entrevoir leur utilite en
matière de recherche et de pratique clinique relativement à l’hy-
pertension. À l’heure actuelle, les etudes proteomiques se concentrent
sur les dommages organiques causes par l’hypertension, ce qui
pourrait nous aider à elucider le lien entre la pression arterielle et
l’insuffisance organique, en plus de nous fournir des biomarqueurs
permettant le depistage precoce de la maladie vasculaire cerebrale ou
coronarienne. À titre d’exemple, on peut citer les facteurs permettant
le depistage precoce de la dysfonction ventriculaire gauche ou de
l’albuminurie. Les etudes metabolomiques, pour leur part, permettent
de tenir compte des facteurs environnementaux et intrinsèques, ce qui
signifie qu’elles sont particulièrement adaptees pour la surveillance de
la reponse au traitement. Nous traitons de diverses etudes « omiques »
relatives à l’hypertension et nous examinons les defis poses par ces
technologies novatrices.
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Volume 33 2017monogenic forms of hypertension is driven mainly by genetics
but can still be modified by environmental factors such as salt
intake and diuretic use. In contrast, essential hypertension
often manifests in concert with conditions such as obesity and
insulin resistance, and blood pressure responds at least to some
extent to lifestyle modifications; despite this, essential hyper-
tension exhibits a high degree of heritability.2,3 If all genetic
and environmental factors could be captured comprehensively
in an individual throughout life, it should theoretically be
possible to precisely map present disease status, future disease
progression, and long-term complications. Indeed, recent
advances in genotyping technologies, such as next-generation
sequencing, have helped address at least the first part of the
equation. Even if our understanding of the complexity of the
human genome, tools to analyze large-scale genetic data, and
knowledge of the links between genetic variation and patho-
physiology of disease are still very limited, one can at least
imagine that a meaningful description of an individual’s
genome is possible. In contrast, a comprehensive description
of all the environmental factors an individual has ever been
exposed to is by far more challenging and probably impos-
sible. As a result, the second part of the equation remains
unknown and can be approximated only by gathering infor-
mation on smoking status, physical activity, social deprivation,
salt intake, and other environmental factors. More compre-
hensive assessment of phenotypes is an important principle of
precision medicine, in which therapeutic approaches are
tailored to the exact condition of the patient. In fact, the term
“phenomics” has been coined based on the “phenome” that
describes the material basis of the phenotype.4
It is this precise characterization of the genotype and
phenotype that can be achieved with omics tech-
nologiesdboth in isolation and combined with other tools,
including imaging techniques, functional testing, and the art
of comprehensive history taking. We briefly describe the 4
main omics technologies that form the focus of this article
before exploring their use in hypertension.Why Does Hypertension Need Omics?
With the paradigm of molecular biology in mind that
DNA is transcribed to RNA and translated to proteins that
then control metabolism, we focus on a comprehensive
assessment of these 4 steps by the means of genomics,transcriptomics, proteomics, and metabolomics. Apart from
these omics technologies, other types of omics play impor-
tant roles in biomedical research: Epigenomics studies the
range of modifications of DNA, eg, by describing genome-
wide DNA methylation data; degradomics studies the
breakdown of proteins by focusing on all proteases, their
substrates, and their inhibitors; and lipidomics is a subtype
of focusing on lipid classes and subclasses. We will not
describe the relevant technical principles in great detail and
instead refer the reader to Table 1 in which these principles
are summarized.
Omics technologies can significantly contribute to our
understanding of the pathogenesis of hypertension, and this
is indeed the area in which much progress has been made
in recent years, especially in genomics. Equally exciting,
there is potential for translation into clinical practice to aid
in the diagnosis and management of patients with hyper-
tension. The areas of research and clinical practice that are
most likely to benefit from omics-based data are presented
in Figure 1.
We outline further how these aims can be addressed in the
future by omics technologies. Before we do this, we discuss
the current state of omics in hypertension. Each individual
omics approach has associated strengths and weaknesses, and
therefore not all technologies are suited for all tasks. It is most
important to recognize that precision medicine cannot rely on
1 technique in isolation; rather, they may be complementary
to one another in characterizing disease processes.Present Status of Omics in Hypertension
In this section, we give an overview of the present work
that has used genomics, transcriptomics, proteomics, and
metabolomics to study various aspects of human hyperten-
sion. This is not a systematic review; rather, it highlights
noteworthy achievements and represents the breadth of
studies that have already been undertaken and the specific
challenges related to them. There are, however, a number of
general challenges that omics-based research has faced in
recent years:
1. The definition of hypertension is not particularly precise
and has changed over time. Of course, this affects all
research into hypertension, but one should be aware of this
Table 1. Challenges related to omics technologies
Challenge Specific issues
All omics technologies involve
the generation of large
amounts of data
Data processing, analysis, and
interpretation is complicated
Statistical tools that help decide which of
the many features that were analyzed are
biologically relevant have been
developed but remain suboptimal
Extensive replication in independent
cohorts and validation and functional
dissection using other methods remain
the cornerstones of scientific work in the
omics era
The complexity of data
depends on the depth of
screening and the particular
omics topic
Single-nucleotide polymorphismebased,
genome-wide association study vs exome
or whole genome sequencing
Single genes can have multiple transcripts
that translate the same gene into
different proteins that can themselves be
post-translationally modified
As a general rule, the complexity of features
is thought to increase in the cascade
from genomics to transcriptomics and
proteomics and probably metabolomics
Precision and coverage of
technologies vary across the
omics topics
By default, at least at the single DNA base
pair level, there are only 4 possible
features (adenine, cytosine, guanine,
thymine), and with current genotyping
technologies these can be assessed
precisely and with virtually 100%
sensitivity and specificity
In contrast, proteomic and metabolomic
technologies are less sensitive and
specific; because of technical restrictions,
no single technology can detect all
possible features, and all these features
cannot be identified precisely
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Omics in Hypertensionlimitation when expectations in the seemingly all-
encompassing omics technologies meet a clinical pheno-
type that is loosely defined and, as stated by Kaplan in
1998, often is not measured accurately.5
2. Essential hypertension is a multifactorial disease, and to
detect these factors, large sample sizes are required. With
the reduced costs of genotyping, very large-scale genomic
studies have been conducted recently, whereas costs for
other omics approaches are still high, studies are labor-
intensive, and available studies are by far not as large as
those in genomics.
3. Hypertension is a disease in its own right but is tightly
linked to its sequelae (eg, vascular stiffening) and to con-
ditions that lead to hypertension (eg, renal diseases).PDiagnosis of 
hypertension
Unraveling the 
pathophysiology 
of hypertension
• Discovering pathogenetic
factors
• Discovering regulatory 
networks and pathways
• Describing the molecular 
makeup of hypertension in 
individual patients
• Molecular definition of 
hypertension
•
•
Figure 1. Applications of omics technologies in hypertensions research. R
Darker colours indicate more urgent needs.Without knowledge of the presence or absence of other
cardiovascular, renal, and metabolic phenotypes, it is
difficult to prove a causal link between molecular features
and hypertension and exclude their association with these
other phenotypes. Large sample sizes with appropriate
statistical adjustment, deep phenotyping, and experimental
studies to dissect the mechanisms are required.6
4. The duration of the development of hypertension and its
association with age is a challenge. Researchers shy away
from long-term longitudinal studies in humans, and most
omics studies are therefore cross-sectional in nature. In
fact, literature searches for the terms “omics” and “hyper-
tension” result in a relatively large number of articles on
pulmonary hypertension and pre-eclampsiadconditions
that develop much faster than essential hypertension.
5. The platforms used for omics research are complex and
require specialist knowledge, and results from different
platforms often are not comparable. Without standardiza-
tion and better recognition of strengths and weaknesses of
each approach, clinical translation will be challenging.
6. Although the somatic genome can be studied in virtually
any DNA-containing material, the transcriptome, prote-
ome, and metabolome are much more cell and tissue
specific. Obtaining the right samples for the right clinical
and research questions is therefore particularly important,
and technical aspects of sample handling and conservation
need to be observed.7Genomics
Genomics has probably seen the most dramatic develop-
ment of all omics technologies in the past decade. The British
Genetics of Hypertension (BRIGHT) study that was pub-
lished < 15 years ago still used microsatellite markers and
linkage analysis to provide genome-wide information in 2010
sibling pairs.8 By 2007, the Wellcome Trust Case Control
Consortium was able to analyze a total of 17,000 samples
using chip-based technology to study approximately 500,000
variants across the genome.9 Further development in tech-
nology and reductions in costs have led to larger studies at
even higher resolution.10 These studies have identified > 50
single-nucleotide polymorphisms robustly associated with
hypertension or blood pressure, or both, and related to
functional pathways such as signalling, renal function, and
natriuresis.11
The vast majority of studies were conducted in cohorts that
display a continuum of blood pressure. A notable exception isPrediction and 
monitoring of 
treatment response
rediction of organ 
damage and 
complications
Understanding the link 
between high blood 
pressure and target -organ 
damage
Identifying patients at 
highest risk
• Eg, Pharmacogenomic
approaches
• Tailoring of treatment to an 
individual's molecular 
fingerprint
esearch and clinical needs are shaded blue and green, respectively.
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Volume 33 2017a study that used an extreme case-control design and was
thereby able to detect a statistically significant signal in a
considerably smaller sample size12; the robust association of a
variant within the UMOD gene encoding the protein uro-
modulin in this study is also remarkable in that most other
signals from genome-wide association studies (GWAS) are not
located in or near genes but rather in intergenic regions, where
an immediate functional role of these variants is more difficult
to elucidate. In fact, only a few GWAS signals have been
directly linked to a functional pathway, and each variant
contributes to only minute changes in blood pressure in the
range of 1 mm Hg systolic blood pressure or 0.5 mm Hg
diastolic blood pressure.10
With further advanced technology, we are now in a posi-
tion to sequence individual genes, all exomes, and even the
whole genome quickly at relatively low cost. Results of a large
exome-based study that discovered novel genetic loci associ-
ated with hypertension have been published recently, showing
that rare variants can have larger effects on blood pressure
(> 1.5 mm Hg) than common variants.13 However,
sequencing techniques have also been used to identify variants
in specific genes. Ji et al.14 used this approach to demonstrate
that variants in genes encoding monogenic forms of hyper-
tension are also present in essential hypertension and explain a
significant proportion of blood pressure variability. In individ-
ual patients in whom clinical investigation indicates secondary
hypertension, sequencing analysis has repeatedly identified new
genetic variants and new mechanisms of blood pressure regu-
lation, including KCNJ5 mutations associated with adrenal
hyperplasia and mutations of CACNA1D encoding a voltage-
gated calcium channel causing cause adrenal aldosterone-
producing adenomas in the absence of KCNJ5 mutations.15,16
There is no doubt that genomics has firmly established
itself in hypertension research and has already generated a
wealth of data providing new insights into the physiology and
pathophysiology of blood pressure regulation. Technologies
from chip-based genotyping arrays to next-generation
sequencing are robust and precise, and further improve-
ments can be expected. Most importantly, genomic studies
can be performed in virtually any sample that contains DNA
because the genetic information is the same or at least similar
for the majority of the genome across all cells. In addition, the
genome changes only minimally with advancing age, and any
changes are mostly restricted to the telomeres and to rare de
novo mutations, eg, in the development of tumours. Genomic
analyses can therefore be performed at any age and are thus
particularly suited to preclinical predictive studies in young
individuals.
There are some general caveats, however, that should be
considered. First, even if genes do not change with ageing,
their expression patterns alter substantially. In childhood, a
range of genetic variants are associated with hypertension in
different age groups,17 and the interaction with age and
environmental factors results in varied gene expression be-
tween individuals with the same genotype. Second, although
the genetic sequence does not undergo significant changes
throughout life or in response to external factors, there are
epigenetic modifications such as DNA methylation that affect
the activity of genes and their transcription. Third, because
the genetic sequence itself does not change with the devel-
opment of most diseases (clearly with the exception of mosttumours), somatic genomics is of limited use in mapping the
precise status of cardiovascular diseases such as hypertension.
The main role of genomic data lies in risk prediction.
We do not discuss the important aspect of pharmacoge-
nomics in this article because it is covered in detail in another
article in this series.18 However, it is clear that genomics offers
data for all facets of research and clinical practice, from
dissection of individual pathophysiological principles to pre-
diction of the risk of hypertension developing and its related
complications, as well as to determination of therapeutic
response.Transcriptomics
There are few transcriptomic studies in hypertension. The
reasons for this are probably manifold. First, and this also
applies to the other omics technologies discussed further on,
the transcriptome is much more cell and tissue specific than is
the genome, and the choice of sample matters. Second, the
complexity of data is even higher than that of the genome;
focusing only on genes, there can be multiple transcripts of
the same gene and the importance of intergenic regulatory
sections of DNA are incompletely understood. Third, minute
changes in the regulation of a specific gene can have much
more dramatic downstream effects on translation to protein
and protein or enzyme activity. Currently applied statistical
techniques that focus on fold changes of expression of
individual genes are not able to capture the complexities of
regulatory networks. Fourth, even if technology for
transcriptome-wide screening in the form of microarrays is
available, validation of findings with an independent tech-
nique such as real-time quantitative polymerase chain reaction
is required, which adds to the complexity and costs of the
experiment. Finally, RNA is far less stable than DNA, and
consistent sample handling and processing are crucial for the
generation of high-quality data. All these issues limit the use of
transcriptomics to dedicated questions in a research environ-
ment. Needless to say, however, the transcriptome should be
able to provide much needed information about how the
general potential of the genome is activated and transcribed in
a tissue-specific manner and thereby deliver a unique finger-
print of an individual’s molecular makeup.
A number of research studies have used gene expression
profiling to study patients with hypertension. A study by
Marques et al.19 in renal tissue of patients with hypertension
and normotensive controls highlighted 14 genes that were
differentially expressed in the medulla. Of the genes that were
confirmed in further experiments, REN, encoding renin, and
CD36, encoding CD36, provided important functional in-
sights. The latter is particularly interesting because a study by
Korkor et al.20 in peripheral blood, a material much more
easily obtained in patients with hypertension, also found
regulation of expression of genes involved in major histo-
compatibility complex class II receptor activity and immune
response. Another study in peripheral blood by Stoynev
et al.21 compared gene expression profiles between patients
with hypertension, those with type 2 diabetes, and controls
and found PDGFRB, encoding platelet-derived growth factor
beta, significantly regulated. There were a number of other
genes encoding adhesion molecules and growth factors that
were found to be differentially expressed, but the results
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focused on 84 targets and did not provide genome-wide
coverage.
In hypertensive disorders other than essential hypertension,
there may be lower-hanging fruit with regard to gene
expression studies. In secondary hypertension, in which the
main driving force of elevated blood pressure is known, gene
expression as well as next-generation sequencing studies may
play important roles. For example, in primary hyper-
aldosteronism, such studies can unravel the mechanisms of
autonomous aldosterone production, as reviewed recently by
Monticone et al.22 In rapidly developing hypertensive con-
ditions such as pre-eclampsia, studies can be performed at
different time points to explore changes in regulation and also
with regard to prediction of the development of these con-
ditions. A number of such studies in placental tissue and in
peripheral blood have been performed and highlight differ-
ential regulation of genes, many of which are involved in
immune mechanisms.23-25
Studies into mRNA expression are subject to limited RNA
stability and tissue-specific gene expression, and these issues
also apply to studies of microRNA expression, albeit to a lesser
extent. MicroRNAs are master regulators and can control the
expression of a large number of genes. The same applies to
other noncoding RNAs that may provide important insights
into the pathogenesis of hypertension.26 MicroRNAs are more
stable in biological samples and can be extracted from blood
and urine; there is general consensus that peripheral profiles
from these substances provide at least some meaningful in-
formation about organ-specific expression.27 For example, a
study by Parthenakis et al.28 looked into microRNA profiles
in peripheral blood cells from patients with hypertension and
microalbuminuria. Even if this was a targeted study into a
limited number of microRNAs, it gives an indication of the
potential impact that an omics approach could have. The true
value of microRNA profiling, however, can be seen when it is
used together with mRNA expression data. In fact, the pre-
viously mentioned study by Marques et al.19 benefited from
such data; they not only showed differential REN expression
but also that miR-663 and miR-181a contributed to its
regulation. We have recently shown differential expression of
miR-206 in the development of pre-eclampsia and a link to
expression of IGF1 encoding insulin-like growth factor 1.29Proteomics
We previously reviewed the potential of proteomics in the
field of hypertension in detail.30,31 Proteomics shares many
challenges with transcriptomics and metabolomics.
1. The proteome varies between tissues, and different results
will be obtained depending on the choice of substrate for
analysis.
2. Appropriate and standardized preparation of samples is
essential to enable comparability between studies.
3. The wide concentration range of proteins in biological
samples requires high-sensitivity platforms to detect
proteins and peptides in the lowest concentration range,
and masking of low-concentration proteins by more
abundant proteins (eg, albumin in plasma samples) can be
problematic.4. Depending on the analysis platform, different results can
be obtained. This relates to the concentration range and
molecular weight of proteins that can be detected with a
given platform and the biostatistical prediction/identifica-
tion of source proteins from polypeptides in a sample. A
recent American Heart Association (AHA) statement is
enthusiastic about the potential of proteomics in cardio-
vascular diseases but calls for standardization of protocols
and large-scale funding initiatives to catch up, particularly
with genomics.7
A few recent examples highlight the potential of prote-
omics to identify proteins involved in the pathogenesis of
hypertension. For example, the urinary proteomic study by
Matafora et al.32 described different levels of uromodulin
depending on the UMOD genotype and also found nephrin-1
to be associated with salt-sensitive hypertension. However,
more work has been done in the prediction and diagnosis of
complications of hypertension. Kuznetsova et al.33 used uri-
nary proteomics to develop a panel of peptides that are
characteristic for early diastolic dysfunction in patients with
hypertension. Peptides within this panel were also differen-
tially expressed in patients with overt heart failure and con-
trols, indicating that molecular processes involved in early
stages of organ damage still play a role in advanced disease. A
recent plasma proteomic study by Pena et al.34 in hypertensive
patients and in patients with diabetes identified biomarker
signatures characteristic for transition in albuminuria status,
which could help to identify renal complications of hyper-
tension at an early stage. In a case-control study nested within
the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
cohort, we demonstrated that urinary proteomic signatures
can predict cardiovascular events in hypertensive patients.35
Proteomics is an attractive technology to study specific
hypertensive conditions such as pre-eclampsia. The opportu-
nities lie in the rapid development of the condition, the
possibility of taking serial samples along its development, and
of course the clinical need resulting from the morbidity and
mortality that are associated with pre-eclampsia. A relatively
large number of studies have therefore looked into proteomic
markers of pre-eclampsia.36,37 Many published studies are,
however, characterized by small sample size and lack of
external validation or functional dissection of findings. A
noteworthy exception is a study by Myers et al.,38 who
combined unbiased screening with targeted validation in in-
dependent discovery and validation cohorts to build various
predictive biomarker panels. However, even this relatively
large and externally validated study would not be able to
“compete” with genetic and genomic studies in this field and
generally in hypertension, indicating again the complexity of
and lack of large-scale funding for proteomic studies.Metabolomics
In metabolomic research, we also see the use of different
platforms, some of which are mass spectrometryebased, as are
many contemporary proteomic approaches; others are based
on nuclear magnetic resonance (NMR) spectroscopy or on
arrays specific for a range of metabolites. Targeted and non-
targeted approaches and the use of different platforms that all
cover only a certain range of metabolites can make it difficult
606 Canadian Journal of Cardiology
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driven by the availability of substrates and enzyme activity and
is thereby a few steps further away from the genome than, eg,
the transcriptome and the proteome. It is therefore particu-
larly well suited to assess environmental influences and the
current state of the organism, not least because the metab-
olome adapts quickly to physiological and pathophysiological
conditions.
Few studies have used metabolomic techniques to identify
metabolites causally linked to the pathogenesis of hyperten-
sion. One recent study identified the dicarboxylic acid hex-
adecanedioate to be associated with hypertension and
mortality and demonstrated that oral hexadecanedioate
increased blood pressure and vascular response to noradrena-
line in Wistar-Kyoto rats.39 Another recent study identified a
number of metabolites associated with a higher risk (serine,
glycine, and acyl-alkyl-phosphatidylcholines C42:4 and
C44:3) or a lower risk (diacyl-phosphatidylcholines C38:4
and C38:3) of incident hypertension over a 10-year period40
This study does not benefit from external validation, and
functional dissection of the results has not yet taken place.
Nevertheless, the idea that metabolic changes precede the
development of hypertension is in keeping with both our
concept of the pathophysiology of the condition and the
interaction between genetic and environmental factors,
rendering the data appealing. Regarding the prediction of
target-organ damage, in an NMR spectroscopy-based meta-
bolic study, Zhang et al.41 found associations between echo-
cardiographic indices of left ventricular diastolic function and
a range of circulating metabolites involved in energy substrate
use and protection against oxidative stress.
The greatest potential of metabolomic studies in hyper-
tension may, however, lie in the monitoring of treatment
responses. Rotroff et al.42 demonstrated that metabolite pro-
files change in response to treatment with hydrochlorothia-
zide, differ between ethnicities, and are able to predict
treatment success. The same group of authors also used these
data together with genomic data in an integrative analysis to
identify genetic markers that predict response to hydrochlo-
rothiazide in a study by Shahin et al.43 Importantly, the
recently developed assays for comprehensive monitoring of
drug metabolites in urine use metabolomic approaches and
have already been introduced into clinical practice to assess
adherence to therapy.44Interactome and Systems Biology
Following the molecular biology paradigm from gene to
protein and metabolite, it appears reasonable to assume that
genomic, transcriptomic, proteomic, and metabolomic studies
detail the same phenomena from different angles. Combining
the information from different omics technologies should
provide a more holistic view of processes involved in physi-
ology and pathophysiology. This integrative approach that
describes the interactome is the basis of systems biology.
There are currently no truly comprehensive interactome data
in human hypertension available. However, the tools to bring
complex data together are being developed, and some exam-
ples show the direction in which this research is heading. In a
study by Atanur et al.45 in rat models of hypertension that
underwent extensive genotyping and phenotyping, loci forstrain-specific disease processes and loci that overlap between
strains as well as with loci for human traits have been iden-
tified. The biostatistical and bioinformatic tools used to
analyze this extremely complex data set can inform similar
analyses in human data sets. Other rodent studies used sys-
tems biology approaches to place proteomic data into larger
disease pathways, identifying dysregulated networks and pre-
dicting further targets from such analyses.46,47 In human
hypertension, 2 recent studies by Marrachelli et al.48,49
combined metabolomic and genomic data to study factors
associated with microalbuminuria and a range of car-
diometabolic risk factors. The previously mentioned article by
Shahin et al.43 is another example of the integration of genetic
and metabolomic data.
The potential of systems biology approaches to study the
pathophysiology of hypertension and other vascular diseases is
evident.50 Integrating data from different omics approaches
may even help to overcome some of the limitations of indi-
vidual technologies by looking at a broader picture of disease
networks rather than at specific compounds in isolation.Future Role of Omics in Hypertension: Focus on
Clinical Applications
Predicting the future of omics in hypertension is of course
impossible, but we can draw a picture that is based on past
and present achievements and the unmet needs in research
and clinical practice. It is clear that omics technologies that are
already far advanced and have generated large amounts of
data, in particular genomics, are more likely to continue
playing a major role in the years to come when compared with
other technologies that are still in their infancy. In keeping
with the maturity of genomics research, recent statements by
the AHA therefore outline very precisely the future use of
genomics for translational and clinical implementation.51,52
However, the huge potential impact of proteomics and
other omics technologies in cardiovascular research and clin-
ical practice has also been acknowledged by the AHA.7 We
highlight a few areas in hypertension that will most likely
benefit from omics technologies in the near future.
Diagnosis of hypertension
It is clear that the diagnosis of hypertension will continue
to be based on blood pressure measurements; there is no need
for complex omics tests to replace a simple diagnostic pro-
cedure. However, omics data can provide detailed insight into
the makeup of hypertension in individual patients and
therefore supplement established diagnostic procedures to
direct therapies.
When it comes to clinical applications, we see in the first
instance a role for genomic studies. The genome remains
virtually static throughout life and always defines a potential
or risk, whereas the transcriptome, proteome, and metab-
olome not only change throughout life but also change in
response to disease processes, making it more difficult to
differentiate between cause and consequence. Currently, ge-
netic techniques are already applied in the diagnosis of rare
forms of hypertension or to classify subtypes of adrenal tu-
mours; in the latter case there can be organ-specific mutations
that would not be detectable in a somatic genetic screen,
which would probably be most useful in patients with
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tant in a research setting but may not find their way into
clinical practice in the very near future.
Prediction of hypertension
Identifying patients at risk at an early stage of the disease
process is a generally attractive concept. With deeper under-
standing of the genetic determinants, the prediction of hy-
pertension later in life is already possible to some extent using
genetic risk scores.53 The genetic background of an individual
is the prime driver of risk but will be modified by the envi-
ronment, which forms the basis for preventive strategies such
as lifestyle modifications to prevent or delay the onset of hy-
pertension. It can be expected that early and subclinical stages
of hypertension will be characterized by alterations in gene
and protein expression. Detection of altered profiles using
transcriptomic, proteomic, and metabolomic techniques could
provide information about which patients are on a trajectory
toward overt hypertension. We are not in a position to discuss
whether prediction of hypertension would indeed have a
traceable effect on clinical outcomes. The few studies in
prehypertension, such as the Trial of Preventing Hyperten-
sion (TROPHY), showed that the onset of overt hypertension
can be prevented or at least delayed in some patients.54 It is
possible, however, that interventions would be even more
successful if they came earlier and at a stage at which the
molecular alterations toward hypertension are less advanced.
Prediction of complications
Hypertension is also a risk factor for complications such as
heart failure, stroke, and renal failure. Early detection of such
complications and targeted preventive measures remain the
holy grail in the management of patients with hypertension.
Current clinical practice is centred on blood pressure values
and simple clinical markers of organ damage such as albu-
minuria and left ventricular hypertrophy. More sophisticated
cardiovascular phenotyping has been suggested to help target
therapies to those at greatest risk.55
Omics-based signatures may add another aspect to the
assessment of target-organ damage. There are already clinical
studies providing evidence that proteomic signatures can be
reliably detected and linked to subclinical organ damage in
cardiac and renal diseases.56,57 Such signatures, also taking
other omics technologies into account, could be further
developed to obtain a global view of cardiovascular damage in
patients with hypertension. Time will tell whether such
assessment is feasible and can meaningfully impact treatment
decisions.
Stratified clinical trials and targeting of treatment
Before omics-derived data can be translated into wide-
spread clinical use, it must be demonstrated that they can
reliably predict outcomes and inform treatment decisions.
This can be done in the form of stratified clinical trials in
which inclusion into the trial or treatment allocation, or both,
are determined by omics signatures. In fact, this concept is
attractive for funding bodies, researchers, and study partici-
pants, because only those who are at greatest risk will be
exposed to investigational medicines. A trial in patients with
type 2 diabetes at risk of diabetic nephropathy based onproteomic signatures is currently under way,58 and a recently
formed consortium is studying the use of omics signatures to
predict the clinical course of primary hyperaldosteronism with
the aim of precisely targeting treatment for these patients
(http://www.ensat-ht.eu). There are also some attempts to use
specific results from omics screens to inform clinical practice.
For example, variants of the UMOD gene that was discovered
to be associated with hypertension in a GWAS have the po-
tential to predict the antihypertensive response to loop di-
uretics,12 and a clinical trial is currently planned (British
Heart Foundation Clinical Study CS/16/1/31878).
Monitoring of treatment response
In patients with hypertension, treatment response can be
monitored by changes in blood pressure, and in turn the
change in blood pressure modifies cardiovascular risk. How-
ever, although the relationship between blood pressure and
cardiovascular outcome is tight at a population level, it does
not necessarily apply to individual patients; in this case,
additional markers of treatment response could help in clinical
management.
Clearly, genetic markers will be of limited use in this
respect because they are not sufficiently dynamic, but
epigenetic, transcriptomic, proteomic, and metabolomic
markers could well be suited to assess treatment response.
Longer-term changes in proteomic signatures in response to
antihypertensive treatment with the angiotensin-receptor
blocker irbesartan have already been shown,56 and we
referred earlier to changes in the metabolome in response to
hydrochlorothiazide.42
A molecular definition of hypertension
In this section, we have focused on the potential for future
clinical application of omics technologies in hypertension.
Precise diagnosis, prediction of hypertension, prediction of
complications, and targeting of treatment are all cornerstones
of precision medicine and of clinical relevance. There is the
additional aspect of a better understanding of pathophysiology
that will almost automatically accompany these clinical ap-
plications and complement basic and clinical research into the
condition. In other areas, such as pancreatic cancer, we have
witnessed how a deep understanding of the molecular makeup
can help to redefine the disease.59 There is no reason why
comprehensive molecular characterization of hypertension
should not be able to define disease subtypes and lead us away
from a merely blood pressureebased definition of hyperten-
sion in the future.Challenges on the Way Ahead
In this review, we have tried to outline some of the po-
tential of omics technologies in future clinical and research
applications in hypertension. We are convinced that this po-
tential is huge but accept that omics studies in hypertension
are not without challenges.
Targeted assessment of genetic variants, protein bio-
markers, and metabolites is without doubt important in the
diagnosis and management of some patients, in particular
patients with secondary forms of hypertension. In contrast,
primary (essential) hypertension is a multifactorial condition
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makeup, even between patients at the extremes of the blood
pressure distribution.3 There is currently no evidence that
comprehensive assessment of large numbers of genetic vari-
ants, proteins, and metabolites provides information beyond
investigations that form the basis of contemporary clinical
practice in these patients. One reason for the lack of trans-
lation to the clinic is the complexity of omics data. Results are
difficult to interpret and to contextualize clinically in indi-
vidual patients. The other reason is related to the costs of
omics studies. With advancing technology, we have witnessed
cost reductions, especially in the areas of genomics and exome
sequencing. The National Human Research Institute states
that “the cost to generate a high-quality ’draft’ whole human
genome sequence in mid-2015 was just above $4,000; by late
in 2015, that figure had fallen below $1,500. The cost to
generate a whole-exome sequence was generally below
$1,000” but acknowledges that it is difficult to provide esti-
mates for these figures (https://www.genome.gov/27565109/
the-cost-of-sequencing-a-human-genome). In the areas of
proteomics and metabolomics, costs are even more difficult to
estimate because of the wide range of available technologies. It
should be noted that in most clinical studies, targeted ap-
proaches to assess proteins and metabolites have been applied;
these may be relatively inexpensive but can provide informa-
tion on only limited numbers of molecules and are not truly
comprehensive omics approaches. There is a body of literature
that assesses the cost-effectiveness of biomarker screening
before the initiation of primary cardiovascular disease in-
terventions, as discussed in a systematic review produced by
the Belgian Health Care Knowledge Centre.60 These studies
are not necessarily of the highest scientific quality, and in the
Belgian review, only 1 article on the value of high-sensitivity
C-reactive protein testing in cardiovascular diseaseefree in-
dividuals compared this biomarker with traditional risk
scoring.61 Detailed health economic analyses into novel bio-
markers including data derived from omics studies are
currently not available in cardiovascular diseases in general or
in hypertension in particular.
We have focused our review on studies in humans but
appreciate that in light of the already available wealth of omics
studies, it is now important to further dissect these findings
and understand the pathophysiology and potential therapeutic
benefit related to these data. Studies in well-established animal
models (spontaneously hypertensive rat, deoxycorticosterone
acetate renovascular hypertension) could demonstrate that the
omics approach accrues new additional data, could establish
the tools to analyze and integrate such data, and in fact could
demonstrate that “interactome” analysis is possible and pro-
vides meaningful information. Some of this work has already
been achieved in rodent models.45,62 Another underexplored
area is the study of omics data in mendelian and other forms
of secondary hypertension in which key pathophysiological
pathways are known and the value of additional insights can
be judged against existing knowledge. Such studies are
currently under way in primary aldosteronism (www.ensat-ht.
eu).
Against this background, it is important to focus on key
steps toward the implementation of omics technologies in
hypertension. The first is to raise awareness of the global
burden of hypertension and the need for more precisediagnosis and treatment. The second is to exploit existing
omics data by translating key findings, especially from GWAS,
into mechanistic and clinical studies; in light of the high costs
of omics research, it will be difficult without such clinical
success stories to “compete” with other areas in medicine. The
third is to not only focus on the molecular aspects of hyper-
tension but also to improve on the clinical characterization of
patients, eg, by using ambulatory blood pressure data as the
basis for omics studies as opposed to nonstandardized office
blood pressure readings. Finally, we must standardize and
streamline research in transcriptomics, proteomics, and
metabolomics in the same way that genomic consortia have
been established in recent years to pool data sets and financial
resources of a size and quality never before seen in hyper-
tension research.Funding Sources
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